XFOR - X4 submits New Drug Application to FDA for WHIM syndrome drug
2023-09-05 12:07:16 ET
More on X4 Pharmaceuticals
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals
- Financial information for X4 Pharmaceuticals
- X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market
- X4 Pharmaceuticals, Inc. ( XFOR ) Q2 2023 Earnings Call Transcript
- X4 Pharmaceuticals: Mavorixafor Could Change Chronic Neutropenic Treatment Landscape
For further details see:
X4 submits New Drug Application to FDA for WHIM syndrome drug